Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

NCT03197870 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03197870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03197870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 (Razuprotafib)15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2017
Completion date
February 9, 2019
Enrollment
167 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

nonproliferative diabetic retinopathy